Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
Omega Fund VI and related reporting persons have disclosed a significant ownership position in ImageneBio, Inc. common stock. They report beneficial ownership of 936,222 shares, including 480,861 shares underlying pre-funded warrants held by Omega Fund, representing 8.4% of the company’s common stock.
The stake was built through ImageneBio’s (formerly Ikena Oncology) IPO, a 2025 PIPE financing and a 2026 PIPE financing. In 2026, Omega Fund bought pre-funded warrants for 480,861 shares at $5.199 per warrant share for total consideration of $2,499,996, as part of a broader $30 million pre-funded warrant issuance.
The warrants have a $0.001 exercise price, are exercisable at any time and do not expire, but contain a beneficial ownership limitation capped at 19.99%. The reporting persons describe the holding as an investment and indicate they may discuss strategic, governance, or transactional matters with ImageneBio’s board and other stockholders while reserving flexibility to increase or reduce their position.
ImageneBio, Inc. principal accounting officer Robert B. Lally filed an initial statement of beneficial ownership, reporting his equity interests in the company. He holds 58,778 shares of common stock, including 56,940 restricted stock units, plus an employee stock option for 25,410 shares at $6.20 per share expiring on March 15, 2036.
ImageneBio, Inc. director Su Wei-guo has filed an insider ownership report showing no reportable transactions or derivative positions. The filing’s transaction summary lists zero buys, zero sells, zero exercises, and no gifts, tax withholdings, or restructurings, indicating a baseline disclosure without trading activity.
ImageneBio director–affiliated investment funds made a sizable indirect purchase of pre-funded warrants. On the April 14, 2026 closing of a private placement, OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P. acquired pre-funded warrants to buy a total of 721,292 shares of ImageneBio common stock at a price of $5.199 per warrant. These pre-funded warrants are exercisable at $0.001 per share and include a 19.99% beneficial ownership blocker. After the transactions, the OrbiMed funds also indirectly held 753,062 and 20,691 shares of common stock, and all entities, including director Bonita P. David, disclaim beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. reported that funds affiliated with OrbiMed purchased pre-funded warrants in a private placement. OrbiMed-related vehicles acquired pre-funded warrants to buy up to 721,292 shares of common stock at a price of $5.199 per warrant, with an exercise price of $0.001 per share.
The pre-funded warrants are exercisable at any time after issuance, subject to a 19.99% beneficial ownership blocker, and expire once fully exercised. The securities are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed entities and their principals disclaiming beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of Common Stock for resale by identified selling stockholders. The supplement incorporates a Form 8-K disclosing a related private placement of pre-funded warrants to purchase up to 5,770,335 Warrant Shares at $5.199 per Warrant Share for gross proceeds of approximately $30 million, with the pre-funded warrants exercisable at $0.001 per share and subject to beneficial ownership limits (including 19.99%). The registration covers resale by selling holders; proceeds from those resales will go to the selling holders, not the company.
ImageneBio, Inc. entered into a private placement on April 12, 2026, agreeing to sell pre-funded warrants to institutional and accredited investors for approximately $30 million of gross proceeds. The warrants cover up to 5,770,335 shares of common stock at a purchase price of $5.199 per Warrant Share, with a nominal exercise price of $0.001 per share and no expiration until fully exercised.
The warrants include a beneficial ownership cap that prevents any holder from exceeding 19.99% ownership through exercise. In a related Registration Rights Agreement, the company commits to file a resale registration statement for the warrant shares within three business days following August 1, 2026, with cash penalties if it fails to meet certain registration obligations. ImageneBio plans to use the net proceeds, together with existing cash, to support late-phase development readiness in atopic dermatitis and to expand development of its IMG-007 program into additional indications, including alopecia areata.
ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received new equity awards as part of her compensation. She was granted an option to buy 128,100 shares of common stock at an exercise price of $6.20 per share, vesting over four years starting March 15, 2027. She also received 85,400 restricted stock units, each convertible into one share of common stock, with 25% vesting on March 15, 2027 and the rest in equal quarterly installments over the following three years, subject to continued service.
ImageneBio, Inc. announced that it has agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. After that date, she will no longer serve as the company’s Principal Accounting Officer and is expected to receive severance benefits under her existing Severance Rights Agreement.
The board of directors has appointed Bob Lally, age 63, currently Senior Vice President, Finance & Operations, to serve as Principal Accounting Officer effective as of the same date. The filing describes Mr. Lally’s prior senior finance and operations roles at Ikena Oncology, Prevail Therapeutics and Arsanis, and notes he did not enter into any new material agreement, has no family relationships with directors or officers, and is not involved in related-party transactions requiring disclosure.